TRANSDERM SCOP Drug Patent Profile
When do Transderm Scop patents expire, and when can generic versions of Transderm Scop launch?
Transderm Scop is a drug marketed by Baxter Hlthcare Corp and is included in one NDA.
The generic ingredient in TRANSDERM SCOP is scopolamine. Twelve suppliers are listed for this compound. Additional details are available on the scopolamine profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Transderm Scop
A generic version of TRANSDERM SCOP was approved as scopolamine by PADAGIS US on January 30th, 2015.
US Patents and Regulatory Information for TRANSDERM SCOP
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baxter Hlthcare Corp | TRANSDERM SCOP | scopolamine | SYSTEM;TRANSDERMAL | 017874-001 | Approved Prior to Jan 1, 1982 | AB | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
